Actualités

Publications

Combination of acamprosate and baclofen (PXT864) as a potential new therapy for amyotrophic lateral sclerosis, J NeuroScience Res, 2020;98[12]:2435-2450
˪ Boussicault L et al
August 19, 2020

Synergistic PXT3003 therapy uncouples neuromuscular function from dysmyelination in male Charcot–Marie–Tooth disease type 1A (CMT1A) rats, J NeuroScience Res, 2020;98[10]:1933-1952
˪ Prukop T, et al
June 26, 2020

Next-generation drug repurposing using human genetics and network biology. Cur Op Science Direct 2020;51:78–92
˪ Nabirotchkin S, et al
January 22, 2020

Baclofen, Naltrexone and Sorbitol all contribute to the efficacy of PXT3003 in CMT1A Rats. EMJ Neurol, 2019;7[1]:47-49. AR6
˪ Hajj R, et al
August 13, 2019

Les traitements pharmacologiques des douleurs neuropathiques. Therapies 2019;1:760
˪ Bouchenaki H, et al
April 13, 2019

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A). PLoS One. 2019 Jan 16;14(1)
˪ Prukop T, et al
January 16, 2019

Parkinson Disease Therapies and Drugs. Pathology, Prevention and Therapeutics of Neurodegenerative Disease, Chapitre 13, pp 151-158
˪ Hajj R
September 25, 2018

Skin Biopsy Findings in Patients With CMT1A: Baseline Data From the CLN-PXT3003-01 Study Provide New Insights Into the Pathophysiology of the Disorder. J Neuropathol Exp Neurol. 2018 Feb 2;1-8
˪ Duchesne M, et al
February 2, 2018

Direct double-blind analysis arguing for synergistic therapeutic effect of a fixed low-dose combination of acamprosate and baclofen in patients with AD. 2017 Nov 1-4. CTAD Poster #LBP32BIS
˪ Touchon J, et al
November 1, 2017

A Rasch Analysis of the Charcot-Marie-Tooth Neuropathy Score (CMTNS) in a Cohort of Charcot-Marie-Tooth Type 1A Patients. PLoS One. 2017 Jan 17;12(1)
˪ Wang W, et al
January 17, 2017